Finally, BID was identified as one of the top 15 candidate genes associated with sensitivity to TTKi in a CRISPR/Cas9 screening of triple negative breast cancer cells, although it was not further investigated [15] and, in a study published when this manuscript was in preparation, Aurora inhibitors combined with BH3-mimetics were shown to induce apoptosis through a pathway involving select BH3-only proteins and CASP-2 [70]. Here, BID is linked to triple-negative breast carcinoma.